Milan, 23rd July 2024
An agreement was signed today between the international investment fund Trilantic Europe and the Italian investment fund Alto Capital IV, managed by Alto Partners SGR, to achieve the aggregation of the industrial centers for third-party pharmaceutical production Doppel Farmaceutici and Mipharm.
The companies will merge into a new industrial entity, controlled by Trilantic Europe and Alto Capital IV with equal shares, which will take the name of Domixtar Pharmaceuticals (abbreviated DMX Pharma) and which will be led by Maurizio Silvestri as Executive President.
Doppel Farmaceutici and Mipharm, starting from a consolidated tradition in the sector, offer a broad portfolio of technologies and products, ranging from solid oral forms (powders, granules, capsules and tablets packaged in sachets, blisters and bottles), to liquid products (drops , injectables and nasal sprays) and semi-solids (soft capsules, creams and suppositories), with a wide range of therapeutic applications among which anti-tumoral, corticosteroids, anti-inflammatory, cardiovascular, metabolic, gastrointestinal, treatment of severe headaches and, moreover, drugs homeopathic products prepared in Alfa Omega, a subsidiary of Mipharm. Thanks to great attention to quality and authorizations obtained from numerous International Drug Agencies including AIFA/EMA for the European markets, USFDA for the US market, the companies serve over 100 customers, including various Big Pharma, spread throughout the world with exports of over 50% of turnover.
DMX Pharma, with a pro forma aggregate turnover in 2023 of approximately 180 million euros, 200 million units produced and 900 employees in its 4 production plants located between Milan, Piacenza and Ferrara, will become one of the largest, totally Italian, groups of pharmaceutical production for third parties and equipped with a modern pharmaceutical technique laboratory capable of supporting its customers in complex R&D projects starting from the experimental phase and product pre-formulation studies up to the scale up of commercial production.
The union of the companies will create strong synergies in both the commercial and technological areas to write a new chapter in their decades-long history, stimulating an organic growth path and laying the foundations for an industrial platform capable of facing a further strategic development at an international level.
The closing of the operation is scheduled for September, as soon as the required authorizations have been received.
